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Summary
Background The WHO Regional Office for the Africa Regional Immunization Technical Advisory Group, in 2011, 
adopted the measles control and elimination goals for all countries of the African region to achieve in 2015 and 2020 
respectively. Our aim was to track the current status of progress towards measles control and elimination milestones 
across 15 west African countries between 2001 and 2019.
Methods We did a retrospective multicountry series analysis of national immunisation coverage and case surveillance 
data from Jan 1, 2001, to Dec 31, 2019. Our analysis focused on the 15 west African countries that constitute the 
Economic Community of West African States. We tracked progress in the coverage of measles-containing vaccines 
(MCVs), measles supplementary immunisation activities, and measles incidence rates. We developed a country-level 
measles summary scorecard using eight indicators to track progress towards measles elimination as of the end of 
2019. The summary indicators were tracked against measles control and elimination milestones.
Findings The weighted average regional first-dose MCV coverage in 2019 was 66% compared with 45% in 2001. 
73% (11 of 15) of the west African countries had introduced second-dose MCV as of December, 2019. An estimated 
4 588 040 children (aged 12–23 months) did not receive first-dose MCV in 2019, the majority (71%) of whom lived in 
Nigeria. Based on the scorecard, 12 (80%) countries are off-track to achieving measles elimination milestones; 
however, Cape Verde, The Gambia, and Ghana have made substantial progress.
Interpretation Measles will continue to be endemic in west Africa after 2020. The regional measles incidence rate in 
2019 was 33 times the 2020 elimination target of less than 1 case per million population. However, some hope exists as 
countries can look at the efforts made by Cape Verde, The Gambia, and Ghana and learn from them.
Funding None.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Worldwide, more than 140 000 people died from measles 
in 2018, despite the availability of an effective, safe, and 
inexpensive measles vaccine licensed since 1963.1 The 
majority of these deaths occurred in sub-Saharan Africa.1 
Measles is highly infectious and can infect up to 90% of 
susceptible contacts.2 Its high infectivity is underscored 
by its basic reproductive number (R0), which is an 
estimate of the number of people in a susceptible 
population that can acquire the disease from a single 
source. Currently, the world is rightly immersed in 
combating infectious disease emergencies such as 
COVID-19 (estimated R0 of 1–3)3 and Ebola virus disease 
(estimated R0 of 2).4 Measles virus infection, with 
an exponentially higher R0 of 12–18, is completely 
preventable with two doses of measles-containing 
vaccine (MCV), but can be spread faster if populations 
are not sufficiently vaccinated.5 Although measles virus 
infection could be self-limiting, in some instances, 
debilitating post-disease sequelae including blindness, 
deafness, and impairment of the immune system occur 
for months afterwards, which leaves children susceptible 
to other deadly infectious diseases.6
In 2012, the American Red Cross, US Centers 
for Disease Control and Prevention, UNICEF, UN 
Foundation, and WHO targeted measles for elimination 
in five of six WHO regions by 2020.7 The key strategies 
were to ensure high vaccination coverage with routine 
vaccinations (ie, MCV first dose [MCV1] and second 
dose [MCV2]), campaign-based supplementary immuni-
sation activities (SIAs) to target subpopulations to 
rapidly scale up coverage,8 and active case-based 
surveillance.7 Consequently, there was a 66% reduction 
in annual measles incidence, a 73% reduction in annual 
measles mortality, and 23·3 million measles deaths 
were prevented between 2000 and 2018.9 Despite this 
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progress, the elimination targets are far from being 
met due to vaccine demand-related issues prevalent in 
high-income countries, recurrent conflicts, and weak 
immunisation systems in low-income countries.9
In 2011, the WHO Regional Office for Africa Regional 
Immunisation Technical Advisory Group adopted the 
Measles elimination: a strategy for the African Region10 
for all member states of the African region of the 
WHO (AFRO) by 2020. As part of this strategy, a measles 
control milestone was set for WHO AFRO countries by 
2015. The milestones for measles control were to reduce 
the annual measles incidence rate to less than five cases 
per million, increase MCV1 and MCV2 coverage to 
90% or more nationally, and 80% or more in all districts, 
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Evidence before this study
We searched for studies investigating trends in measles 
elimination or control in west Africa in the past 2 decades, from 
Jan 1, 2001, to Dec 31, 2019, using PubMed. We used the search 
terms “measles” [all fields] AND “West Africa” [all fields] OR 
“ECOWAS” [all fields] AND “elimination OR control” [all fields]. 
No language restrictions were applied. We included studies that 
were based in west Africa or included at least one west African 
country. Most studies were active case-based surveillances or 
descriptive analyses of routinely collected data. The studies 
focused on either one region within a country, an entire 
country, or comparisons between two and 15 countries. These 
studies investigated ongoing measles outbreaks, assessed 
routine measles vaccine coverages, and assessed the coverage 
and effectiveness of supplementary immunisation activities 
(SIAs) using routinely collected, publicly available data sources. 
We were, however, unable to assess the quality of the data used 
in the active case-based surveillance studies.
Previous studies reported increasing trends in measles cases in 
the region following the 2014–16 Ebola epidemic in the region. 
Studies also projected an accumulation of a large cluster of 
children unvaccinated for measles across Guinea, Liberia, and 
Sierra Leone and an expected increase in the size of regional 
outbreaks projected to result in 2000–16 000 additional deaths. 
A study in Nigeria reported that the national coverage of the 
first dose of measles-containing vaccine (MCV1) was 
consistently low between 2012 and 2015, with wide variations 
between regions within the country. A study also reported that 
despite their high routine MCV1 coverage, most west African 
countries have some programme gaps indicating that they do 
not meet all the criteria to undergo verification of elimination 
at this point. In a report of MCV1 coverage estimates in 2015, 
only two countries in the region had coverage of 95% or more 
for both MCV1 and the second dose of measles-containing 
vaccine (MCV2) whereas five countries had coverage of more 
than 80% for both doses. Dropout rates of more than 20% 
between MCV1 and MCV2 existed in 12 west African countries. 
The report across most studies showed that the MCV2 coverage 
remains low in the region.
The evidence also showed that, in some countries, measles SIAs 
appeared to have successfully reached a higher proportion of 
measles vaccine-naive children compared to others. Across all 
countries, SIAs played an important part in reaching children 
from poor households, reducing the overall magnitude of the 
measles virus outbreak in 2009. A study from Côte d’Ivoire and 
Burkina Faso found that migration of children between both 
countries played a major role in the failure of SIAs to interrupt 
measles transmission.
Added value of this study
This is the first comprehensive analysis, to our knowledge, of 
progress towards the global measles control and elimination 
milestones between 2001 and 2019, exclusively focused on 
15 west African countries. The weighted mean MCV1 coverage 
across the region increased from 45% in 2001 to 66% in 2019. 
However, Benin, Côte d’Ivoire, Guinea, and Guinea Bissau were 
yet to introduce the recommended MCV2 vaccination as of 
December, 2019. There were an estimated 4 588 040 children 
(aged 12–23 months) in the region who did not receive MCV1 
in 2019; the majority (71%) lived in Nigeria. In this analysis, 
we propose a scorecard that highlights key metrics which could 
be used to categorise, track, and compare country-level 
progress towards measles elimination. Based on this, 
12 (80%) countries in the region are off-track to achieving 
measles elimination milestones, while Cape Verde, The Gambia, 
and Ghana have made substantial progress.
Implications of all the available evidence
The available evidence shows that there has been substantial 
progress in MCV1 coverage, MCV2 introduction, and the reach 
of SIAs across the west African region between 2001 and 2019. 
Although there has been an overall reduction in the incidence 
of measles cases per million population, there still exist 
inequalities within and between countries in the region. 
The region did not meet the measles control milestones of 
2015 and is currently off-track to achieve the 2020 elimination 
milestones. Although Cape Verde, The Gambia, and Ghana have 
made substantial strides, the results suggest that, as things 
stand, measles will continue to be endemic in the region well 
into the future in a landscape of a visa-free cross-border 
migration. These findings should inform regional strategies and 
shared learning, which could be coordinated by the region for 
countries to strengthen their routine immunisation systems, 
and ensure local ownership and continued financial 
commitment. Furthermore, countries must conduct well 
targeted and integrated SIAs to reduce the inequality gaps, 
improve case-based surveillance to ensure rapid detection, and 
enhance community engagement to address any vaccine 
demand-related issues. These actions remain even more 
important as more countries within the region graduate from 
eligibility for Gavi, the Vaccine Alliance, support.
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and to achieve 95% or more coverage during measles 
SIAs.7 Furthermore, measles elimination milestones 
were set for the end of 2020. These were, specifically, to 
achieve and maintain annual measles incidence of less 
than one case per million population nationally, 95% or 
more MCV1 and MCV2 coverage nationally and in all 
districts, and at least 95% coverage in all scheduled or 
outbreak-related measles SIAs, among other targets.10
Despite these ambitious elimination targets, since 2019, 
the world’s largest single-nation measles outbreak has 
persisted in Democratic Republic of the Congo, with 
more than 310 000 suspected cases, and resulted in the 
death of more than 6000 people as of January, 2020.11 In 
west Africa, the 2014–16 Ebola outbreak in Guinea, 
Liberia, and Sierra Leone had a crippling effect on 
immunisation systems, leaving behind an additional 
public health crisis of a large connected cluster of measles 
vaccine-naive children.12 The regional risk of sustained 
measles transmission is thought to have been further 
compounded by recurrent humanitarian crises, which 
have caused displacement of people across transnational 
borders.13 In this landscape, we set out to assess the 
region’s trajectory a decade before the measles elimination 
and control strategy was adopted. We then followed up 
the progress for a subsequent decade after the adoption 
of the elimination and control strategy to determine if 
the measles control milestones were achieved in 2015 
and to track the current trajectory towards the measles 
elimination milestones in west Africa.
Methods
Study design
We did a retrospective multicountry series analysis 
of national measles immunisation coverage and case 
surveillance data from Jan 1, 2001, to Dec 31, 2019. This 
analysis focused on the 15 west African countries that 
constitute the Economic Community of West African 
States (ECOWAS). The ECOWAS is an alliance whose 
aim is to promote regional integration and allow visa-free 
trans-border migration for all west Africans.14 The 
15-member regional bloc comprises Benin, Burkina 
Faso, Cape Verde, Côte d’Ivoire, The Gambia, Ghana, 
Guinea, Guinea Bissau, Liberia, Mali, Niger, Nigeria, 
Senegal, Sierra Leone, and Togo. In 2019, the region had 
an estimated population of 387 million, with Nigeria 
accounting for about 52%.15 In 2019, Benin, Cape Verde, 
Côte d’Ivoire, Ghana, Nigeria, and Senegal were lower-
middle-income countries, whereas the remaining nine 
countries were low-income countries.16 All ECOWAS 
countries apart from Cape Verde receive Gavi, the 
Vaccine Alliance support, for their immunisation system, 
with some of these countries scheduled for transition 
from Gavi support in the coming years.17
Data sources
We obtained data from the UN World Population 
Prospects 2019,15 WHO/UNICEF Estimates of National 
Immunization Coverage (WUENIC) database,18 Multiple 
Indicator Cluster Survey (MICS),19 and Demographic and 
Health Survey (DHS; table).20 We used the final 
official yearly reports of the WHO measles surveillance 
database from 2001 to 2019,21 and periodic measles SIAs 
from WHO’s database.22 We also extracted the Joint 
External Evaluation (JEE) scores for each country.23 The 
JEE score uses measles vaccine coverage as one of its 
measures to assess country-level capacity to prevent, 
detect, and rapidly respond to public health risks.23
Estimating MCV1 coverage trends, population reached 
by SIAs, and MCV2 introductions
We obtained MCV1 coverage data from the WUENIC 
database.18 We computed the regional median MCV1 cover-
age and mean MCV1 coverage weighted by each country’s 
corresponding annual surviving infant population from 
2001 to 2019 and plotted a line graph showing the trends. 
Furthermore, the highest and lowest MCV1 coverage 
countries for the corresponding year were illustrated by 
creating two trend lines representing the countries.
To estimate the reach of SIAs, we compared the 
absolute number of the population targeted by SIAs 
Data extracted Years extracted Date accessed
UN World Population Prospects 201915 Country-level estimates of total population and surviving infants for all 15 ECOWAS countries 2001–19 July 15, 2020
WHO/UNICEF Estimates of National Immunization Coverage 
database18
Country-level MCV1 and MCV2 coverage estimates for all 15 ECOWAS countries 2001–19 July 15, 2020
WHO measles surveillance database21 Absolute number of measles cases reported per country for all 15 ECOWAS countries 2001–19 July 15,2020
MICS19* Country-level MCV1 coverage disaggregated by geographical areas 2014–18 July 18, 2020
DHS20* Country-level MCV1 coverage disaggregated by geographical areas 2005–18 July 18, 2020
WHO Immunization Database22 Country-level supplementary immunisation activities for all 15 ECOWAS countries 2001–19 July 21, 2020
JEE mission reports23† JEE scores per country 2016–19 July 21, 2020
DHS=Demographic and Health Survey. ECOWAS=Economic Community of West African States. JEE=Joint External Evaluation. MCV1=first dose of measles-containing vaccine. MCV2=second dose of measles-
containing-vaccine. MICS=Multiple Indicator Cluster Survey. *Data from either the MICS or DHS were extracted depending on which survey was the most recent in the country: Benin (DHS 2017–18), Burkina Faso 
(DHS 2010), Cabo Verde (DHS 2005), Côte d’Ivoire (MICS 2016), The Gambia (MICS 2018), Ghana (DHS 2014), Guinea (DHS 2018), Guinea Bissau (MICS 2014), Liberia (DHS 2013), Mali (DHS 2018), 
Niger (DHS 2012), Nigeria (DHS 2018), Senegal (DHS 2017), Sierra Leone (MICS 2017), and Togo (DHS 2013–14). †2016=Côte d’Ivoire, Liberia, Senegal, and Sierra Leone. 2017=Benin, Burkina Faso, The Gambia, 
Ghana, Guinea, Mali, and Nigeria. 2018=Niger and Togo. 2019=Guinea Bissau.
Table: Summary of the data used in this analysis, their respective sources, and years extracted per country
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across the 15 west Africa countries against the actual 
population reached using SIA data from the WHO’s 
database.22 We tracked the number of countries that 
introduced MCV2 per year across west Africa between 
2001 and 2019 using data from the WUENIC database.18
Estimating the number of children who were 
unvaccinated for MCV1 in 2019
We estimated the absolute number of children 
unvaccinated for MCV1 as the proportion of the 2019 
country-specific surviving infants (based on the UN World 
Population Prospects 2019)15 who did not receive MCV1 
(based on the WUENIC database).18 We illustrated this 
using a bubble map, with the size of each bubble repre-
senting the number of children unvaccinated with MCV1.
Estimating country-level equity in MCV1 vaccination 
coverage
We obtained the most recently available disaggregated 
MCV1 coverage from the MICS and DHS data.19,20 This 
was subsequently mapped according to country-level 
subnational administrative areas into MCV1 coverage 
categories of less than 20%, 20–39%, 40–59%, 60–79%, 
80–94%, and 95% or more. The WHO considers equity as 
an important component of progress towards elimination 
of measles.24 Therefore, we estimated the most recent 
situation of the intracountry geographical equity gap in 
MCV1 coverage using a single summary measure of the 
difference as a proxy for absolute inequity by subtracting 
MCV1 coverage in the subnational administrative area 
with the lowest from that with the highest per country (in 
percentage points). We considered an absolute coverage 
gap of 20% or less as the reference equity benchmark.24
Estimating the number of measles cases
The measles cases were the absolute number of 
laboratory-confirmed, epidemiologically confirmed, and 
clinically confirmed cases reported to WHO per 
country.25 WHO defines laboratory-confirmed measles 
cases as cases that meet the clinical case definition with 
the presence of measles-specific IgM antibodies, and 
epidemiologically confirmed measles cases as cases that 
meet the clinical case definition and are linked to a 
laboratory-confirmed case. Clinically confirmed measles 
cases are defined as cases that meet the clinical case 
definition and for which no adequate blood specimen 
was taken. A clinical case definition included any person 
in whom a clinician suspects measles infection, or 
any person with fever and maculopapular rash (ie, 
non-vesicular) and cough, coryza (ie, runny nose), 
or conjunctivitis (ie, red eyes).25
Estimating the annual measles incidence rate in 
west Africa
Annual measles incidence rate per million was calculated 
by dividing the number of measles cases per year by 
corresponding national population estimates. The 
regional measles incidence rate was, therefore, the 
absolute number of yearly measles cases in west Africa 
divided by the total national population of the 
15 countries in that same year. We illustrated the highest 
and lowest measles incidence rates in the region for 
the corresponding year by creating two trend lines 
representing the country with the highest and lowest 
incidence rates.10
Comparing MCV1 coverage, SIAs, and measles incidence 
rate
We plotted a trend line of the mean regional MCV1 
coverage (weighted by the total regional surviving infant 
population per country) and measles SIAs against the 
mean regional measles incidence rate (weighted by the 
total population per country). Through this approach, we 
highlighted the contribution of increasing and decreasing 
MCV1 coverage and SIA activities on measles incidence 
rates.
Assessing progress towards measles elimination 
(country-level measles summary scorecard)
To assess each country’s progress towards measles 
elimination, we developed a country-level measles 
summary scorecard as of the end of 2019. The scorecard 
was developed in response to the 2016 Mid-term Review of 
the Global Measles and Rubella Strategic plan 2012–2020 
that encouraged countries to develop standard methods to 
categorise progress and the likelihood of achieving the 
measles milestones.26 The scorecard comprised eight 
country-level indicators: 2015 MCV1 coverage (tracked 
against the 90% control milestone); MCV1 coverage as of 
2019 (tracked against the 95% elimination milestone); 
2015 MCV2 coverage (tracked against the 90% control 
milestone); MCV2 coverage as of 2019 (tracked against 
the 95% elimination milestone); geographical equity gap 
in MCV1 coverage (tracked against the benchmark of 
≤20% points);24 2015 measles incidence rate (tracked 
against the control milestone of <5 cases per million); 
measles incidence rate as of 2019 (tracked against the 
elimination milestone of <1 case per million);10 and JEE 
scores, reported as dark green for scores 4 and 5, yellow 
for scores 2 and 3, and red for score 1.23
According to WHO and UNICEF, MCV1 and MCV2 
coverage was categorised as dark green if at least  90% in 
2015, or at least 95% in 2019; light green if 80–89% in 2015 
and 80–94% in 2019; yellow if 50–79%; or red if 50% or less. 
Countries yet to commence MCV2 as of December, 2019, 
were also categorised as red. Measles incidence rate per 
million was categorised as dark green if for less than 
5 cases per million in 2015 and less than 1 case per million 
in 2019; light green if 5–9 cases per million in 2015 and 
1–4 cases per million in 2019; yellow if 10–19 cases per 
million in 2015 and 5–9 cases per million in 2019; and red 
if more than 20 cases per million in 2015 and more than 
10 cases per million in 2019. Intracountry geographical 
equity gap was categorised as dark green if 20% or less 
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points and red if more than 20% points. JEE scores were 
categorised as red if 1, yellow if 2–3, and dark green if 4–5.
All eight indicators were weighted equally, giving a 
total score of eight. We considered a country that achieved 
dark or light green in at least six indicators to have made 
substantial progress. Countries that achieved dark or 
light green in three to five indicators were considered to 
have made borderline progress. In contrast, countries 
that achieved two or less were considered to have made 
little progress towards measles elimination.
We did a mini validation of the scorecard using 
data from countries in the WHO South-East Asia region. 
We selected this region because the measles virus infection 
is endemic, and MCV1 and MCV2 are routinely adminis-
tered. All countries with complete dataset required to 
generate the scorecard were included. We calculated the 
sensitivity and specificity of the scorecard for correctly 
identifying countries with substantial progress, when 
compared with the WHO measles elimination certification 
for those countries as gold standard. The scorecard showed 
a 75% sensitivity and specificity (appendix pp 2–17).
All figures were generated using Microsoft Excel 
(Microsoft, Seattle, WA, USA), whereas the disaggregated 
MCV1 coverage map was created using ArcGIS software 
(version 10.4, Environmental Systems Research Institute 
Redlands, CA, USA).
Role of the funding source
The funders of the study did not have any role in study 
design, data collection, data analysis, data interpretation, 
or writing of the manuscript. 
Results
Overall, MCV1 coverage increased across west Africa 
between 2001 and 2019. The weighted mean MCV1 
coverage was 45% in 2001 and increased to an initial 
Figure 1: MCV1 coverage, MCV2 introduction, reach of supplementary immunisation activities, and unvaccinated children in west Africa, 2001–19
(A) Regional median and weighted mean MCV1 coverage in west Africa between 2001 and 2019. Mean MCV1 coverage weighted by each country’s total surviving infant population as a proportion of the 
surviving infant population in west Africa per year. (B) MCV2 introduction in west Africa, 2001–19. (C) Cumulative population targeted and reached by supplementary immunisation activities in west 
Africa, 2001–19. (D) Number of west African children who did not receive MCV1 vaccination per country in west Africa in 2019; the size of each bubble corresponds to the absolute number of unvaccinated 
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peak in 2009 (69%). However, this increase in weighted 
mean MCV1 coverage was followed by an average yearly 
decline of 2% until it reached a coverage of 59% in 2015 
before rising sharply to 72% in 2017 and declined 
afterwards (figure 1A). The highest country-level MCV1 
coverage ranged from 89% in 2001 to 99% in 2019, with 
Cape Verde and The Gambia consistently reporting the 
highest coverage. The first west African country to 
introduce MCV2 was Cape Verde in 2011, followed by 
The Gambia and Ghana in 2012. By 2019, 73% (11 of 15) 
of countries in the region had introduced MCV2; 
Benin, Côte d’Ivoire, Guinea, and Guinea-Bissau 
had not yet introduced the vaccine (figure 1B). The 
population targeted for SIAs in the region increased 
consistently between 2009 and 2019 with the actual 
population reached surpassing the targeted population 
during the same period (figure 1C). There were an 
estimated 4 588 040 children (aged 12–23 months) 
across the 15 west African countries who did not receive 
MCV1 in 2019. A majority (71%) of these children lived 
in Nigeria, which also accounted for 53% of the regional 
13 474 000 surviving infant population in 2019 (figure 1D).
Of the total 166 subnational administrative areas 
across the 15 west African countries, 11 (7%) had 
achieved MCV1 coverage of at least 95%. The 11 sub-
national administrative areas were Resto Santiago, 
Fogo, and Brava in Cape Verde; Nord, Plateau Central, 
Sahel, and Sud-Ouest regions in Burkina Faso; Upper 
East and Upper West regions in Ghana; and Kedougou 
and Sedhiou regions in Senegal. More than 80% of the 
subnational administrative areas in Cabo Verde (11 of 
12 regions), Burkina Faso (11 of 13 regions), The Gambia 
(all regions), Ghana (nine of ten regions), and Senegal 
(11 of 14 regions) had MCV1 coverage of at least 80% 
(figure 2). The highest cumulative number of measles 
cases was 299 361 reported in 2001, whereas the lowest 
was 1709 measles cases reported in 2006 (figure 3A). 
The number of cases almost tripled between 2017 and 
2019 (17 653 in 2017 vs 47 819 cases in 2019). There were 
no measles cases reported in Cape Verde between 2001 
and 2019. The weighted mean measles incidence rate 
ranged between 909 cases per million to six cases per 
million population in west Africa (figure 3B). The 
lowest (six cases per million) weighted mean incidence 
rate was in 2006 and 2007, whereas the highest (909 
cases per million) was in 2001. Benin, Liberia, Niger, 
and Sierra Leone repeatedly had the highest measles 
incidence rate in the period under study.
Overall, there was an inverse relationship between the 
weighted mean MCV1 coverage and weighted mean 
measles incidence rate (figure 4A). As the weighted mean 
MCV1 coverage increased between 2001 and 2019, the 
weighted mean measles incidence rate per million 
decreased. Similarly, an inverse relationship was also 
observed between the number of children reached by 
SIAs and the weighted mean measles incidence rate in 
west Africa (figure 4B).
Cape Verde, The Gambia, and Ghana made substantial 
progress towards measles elimination (figure 5). On the 
other hand, Benin, Burkina Faso, Côte d’Ivoire, Guinea, 
Figure 2: Map of west Africa showing disaggregated MCV1 coverage (%) by subnational administrative areas (regions or states) across the 15 ECOWAS 
countries
The most recently available, disaggregated national survey data used per country. Benin (DHS 2017–18), Burkina Faso (DHS 2010), Cape Verde (DHS 2005), Côte d’Ivoire 
(MICS 2016), Gambia (MICS 2018), Ghana (DHS 2014), Guinea (DHS 2018), Guinea Bissau (MICS 2014), Liberia (DHS 2013), Mali (DHS 2018), Niger (DHS 2012), Nigeria 
(DHS 2018), Senegal (DHS 2017), Sierra Leone (MICS 2017), and Togo (DHS 2013–14). DHS=Demographic and Health Survey. ECOWAS=Economic Community of West 
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Liberia, Mali, Niger, Nigeria, and Sierra Leone have made 
little progress towards measles elimination having 
achieved the benchmark of only one or two of the eight 
measles summary indicators.
Discussion
To our knowledge, this analysis represents the first 
comprehensive regional level estimation of progress 
towards measles elimination targeted at the 15 ECOWAS 
countries. Since 2001, the region has made progress in 
increasing MCV1 uptake, introducing MCV2 across 
many countries, increasing the reach of measles SIAs, 
and reducing the incidence rate of measles per million 
population. Nevertheless, progress has been far from 
universal, even though most of the countries in the 
region have received Gavi support since 2000 to finance 
strategies to address country-level immunisation gaps. 
Measles control milestones were not met in most 
countries in 2015 and progress towards the elimination 
milestones are off-track in the region. Substantial 
variation within and between countries persist in MCV1 
coverage, MCV2 introduction, and measles incidence 
Figure 3: Measles cases and measles incidence rate per million population in 
west Africa, 2001–19
(A) Cumulative number of reported measles cases per year. The number of 
measles cases for Togo during this period were quite small compared with other 
countries, thus, they are not visible in this figure. (B) Measles incidence rate per 
million population between 2001 and 2019 based on available country-level 
cases reported to WHO in 15 west African countries. Cape Verde consistently 
reported the lowest measles incidence rate of zero per million population. 
Country-level population was based on the UN World Population Prospects 2019.
Figure 4: Relationship between MCV1 coverage, SIAs, and measles incidence 
rate per million population in west Africa, 2001–19
(A) Relationship between weighted mean MCV1 coverage and weighted mean 
regional measles incidence rate in west Africa, 2001–19. (B) Relationship 
between measles SIAs and weighted mean measles incidence rate in west Africa, 
2001–19. Some countries did more than one SIA per year. MCV1=first dose of 
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rates, with, for example, regional measles incidence rate 
as of 2019 being more than 33 times the elimination 
target of less than 1 per million population by the end 
of 2020.
Cape Verde, The Gambia, and Ghana have made 
substantial progress and are on track to achieving the 
measles elimination milestones by 2020. This finding 
aligns with previous research on immunisation system 
performance in the region, which reported that Cape 
Verde and The Gambia had achieved the Global Vaccine 
Action Plan immunisation coverage and dropout targets 
since 2015.27 Other factors might explain the progress 
made by Cape Verde, The Gambia, and Ghana. Cape 
Verde and The Gambia are less populated (0·54 million 
people in Cape Verde and 2·1 million people in The 
Gambia)15 than other countries in the region. The majority 
of Gambians live within a convenient distance from a 
health facility, and the government regularly provide 
immunisation services using outreach clinics to target 
hard-to-reach subpopulations.28 This unique characteristic 
makes the delivery of immunisation services more 
efficient. This is seen in southeast Asia where Bhutan 
(population 0·76 million people), Maldives (0·54 million), 
and Timor-Leste (1·3 million),15 are the three of five 
countries that have eliminated measles in that region.
The population of a country, however, only provides 
a partial explanation for progress towards measles 
elimination. Ghana has a comparable population size to 
Côte d’Ivoire, which has made limited progress towards 
achieving the elimination milestones.15 Compared to other 
countries in the region, the health system in Ghana is 
considered well integrated and well financed, and 
implements up-to-date policies aimed at providing 
essential services, including immunisation.29 For example, 
Ghana is currently implementing the third comprehensive 
multi-year plan to provide strategic direction for 
immunisations in the country to meet national priorities 
and global targets. The current (2015–19) comprehensive 
multi-year plan being implemented for the Expanded 
Programme on Immunization follows the successful 
implementation of previous plans which have improved 
access and use of immunisation services in the country.30
Benin, Burkina Faso, Côte d’Ivoire, Guinea, Liberia, 
Mali, Niger, Nigeria, and Sierra Leone have made little 
progress towards achieving the global measles 
elimination milestones. In most of these countries, a 
complex mix of suboptimal MCV1 and MCV2 coverage, 
non-introduction of MCV2, a wide intracountry geo-
graphical equity gap in MCV1 coverage, and a double-
digit measles incidence rate per million population 
persist. In 2001, WHO designated these nine countries 
among others as priority countries for measles 
elimination.7 Nonetheless, the pervasive measles-related 
issues seem to have persisted after almost two decades 
of adopting the ambitious strategic plan. With an 
overwhelming proportion of the estimated 4·5 million 
measles vaccine-naive children in west Africa resident 
in these nine countries, the region faces an ongoing, 




















Benin 67 79 0 0 49·5 5·2 37·0 2 1
Burkina Faso 88 88 50 71 25·1 5·5 33·1 3 3
Cape Verde 92 98 95 91 15·3 0·0 0 || 7
Côte d'Ivoire 67 76 0 0 32·3 2·8 14·5 3 1
The Gambia 97 85 81 61 9·6 34·0 0·4 4 6
Ghana 89 92 63 83 17 0·8 41·9 4 6
Guinea 48 47 0 0 41 21·3 356·7 3 0
Guinea-Bissau 85 86 0 0 19·3 88·1 31·2 3 3
Liberia 64 85 0 13 21·5 237·0 243·7 3 1
Mali 62 70 0 4 78·4 12·0 23·1 3 0
Niger 85 79 16 58 21 384·6 442·8 3 1
Nigeria 43 54 0 9 36·4 68·6 139·8 3 0
Senegal 80 90 54 78 50·5 4·0 16·4 3 3
Sierra Leone 78 93 60 72 13·6 84·6 5·1 3 2
Togo 75 75 0 67 22·7 2·6 8·5 3 1
MCV2 coverage (%)* Measles incidence rate
per million‡
Figure 5: Scorecard summary showing achievement of measles elimination milestones across countries in the west African region
JEE=Joint External Evaluation. MCV1=first dose of measles-containing vaccine. MCV2=second dose of measles-containing-vaccine. *MCV1 and MCV2 coverage categories: 
dark green=≥90% in 2015 and ≥95% in 2019; light green=80–89% in 2015 and 80–94% in 2019; yellow=50–79%; and red=≤50%. As of December, 2019, Benin, 
Côte d’Ivoire, Guinea, and Guinea-Bissau had not yet commenced MCV2 immunisation. †Intracountry geographical equity gap categories: dark green=≤20% points and 
red=>20% points. ‡Measles incidence rate per million categories: dark green=<5 cases per million in 2015 and <1 case per million in 2019; light green=5–9 cases per million 
in 2015 and 1–4 cases per million in 2019; yellow=10–19 cases per million in 2015 and 5–9 cases per million in 2019; and red=>20 cases per million in 2015 and >10 cases 
per million in 2019. §JEE categories: red=1; yellow=2–3; and dark green=4–5. ¶Country-level measles scorecard categories: dark green=achieved 6–8 of the 8 measles 
summary indicators; yellow=achieved 3–5 of the 8 measles summary indicators; and red=achieved only 1 or 2 of the 8 measles summary indicators. ||JEE yet to be done.
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Ongoing humanitarian crises pose one of the biggest 
obstacles to achieving the measles elimination targets in 
Benin, Burkina Faso, Côte d’Ivoire, Guinea, Liberia, 
Mali, Niger, Nigeria, and Sierra Leone.26 UNICEF 
estimate that two-thirds of the world’s unvaccinated 
children live in conflict-affected countries.31 Burkina 
Faso, Mali, and Niger have experienced repeated deadly 
armed conflicts over the past decade. For more than a 
decade, Nigeria has struggled to curtail violent conflict 
orchestrated by the terrorist group Boko Haram. The 
ensuing humani tarian crises adversely impacted the 
measles elimination strategies due to massive population 
movement within and across national borders, and 
disrupted the delivery of immunisation services.32 
Guinea, Liberia, and Sierra Leone, the three countries at 
the epicentre of the 2014–16 Ebola outbreak, were already 
suffering from low vaccination coverage rates. In the 
wake of the outbreak, several factors led to the disruption 
in routine immuni sation services and underperformance 
of measles vaccination campaigns leaving behind a large 
cohort of unvaccinated children. For example, in Guinea, 
routine immunisation was suspended in many places 
with active Ebola virus transmission. Also, SIA 
campaigns were less effective in some communities that 
struggled with mistrust of public health professionals 
or reduced health seeking behaviour due to the fear of 
being infected with the virus at the health facility—a 
phenomenon that we are seeing during the ongoing 
COVID-19 pandemic.33
Our findings reflect the broader reality in sub-Saharan 
Africa. The 2016 mid-term review of the Global Measles 
and Rubella Strategic Plan 2012–2020 showed that 
despite some impact in AFRO, substantial challenges 
in reaching measles elimination remain.26 Among 
these challenges was recognition of the epidemiological 
shift in disease towards older age groups (adolescents 
and adults) that requires a parallel programmatic 
response.34 The 2015 revised African regional guidelines 
use the WHO-wide guidelines and does not address this 
shift within routine immunisation schedules.35 A 
beyond-2020 strategy should address this issue, must 
prioritise closing immunisation gaps, and focus on 
timely vaccination of all susceptible age groups, 
especially in areas of long-lasting low coverage.
The realities of concurrent outbreaks, humanitarian 
crises, and political unrest will continue to affect 
measles coverage. Future plans must not only 
acknowledge these challenges but reinforce strategies 
within special circumstances accordingly. Like polio, to 
actualise measles elimination, investments must be 
coordinated, consistent, and steady from both national 
governments as well as international partners.36 Com-
pellingly, a clear challenge to this region is the poor 
uptake of MCV1 in Nigeria. With its high proportion of 
infants, this failure highly skews the measles coverage 
performance in west Africa. A combination of overall 
low national immunisation coverage and a geographical 
imbalance of four in every five measles cases being 
from the northern region, requires targeted and 
innovative approaches to increase coverage rates.37 
Other approaches to improving coverage in Nigeria and 
similarly high-burden countries include spatial analysis 
of coverage gaps to inform more targeted campaigns as 
well as a successful transition of polio infrastructure to 
shore-up measles surveillance as vertical polio 
programmes diminish following the recent wild polio-
free certification in the African region.
The datasets and methods used in this analysis might 
be subject to some limitations. First, the DHS and MICS 
immunisation coverage data used to generate the 
disaggregated MCV1 coverage map were survey-based, 
collected from vaccine cards and maternal recall. 
Although the DHS and MICS surveys provide 
disaggregated immuni sation coverage data at 
subnational and district level compared with the non-
disaggregated WUENIC coverage estimates, they are 
also prone to recall bias. Second, the DHS and MICS 
data used were from varying years (2005–18). Although 
the varying years of the data might limit direct temporal 
comparison in terms of the current status of in-country 
equity in MCV1 coverage, we only resorted to the best 
available data sources. Third, there are gaps in reporting 
of measles cases to WHO, which is due, in part, to an 
underlying differential quality or sensitivity of case-
based surveillance at country-level.38 Thus, the measles 
cases presented in the analysis might not reflect the true 
situation and makes intercountry comparison difficult. 
Fourth, we acknowledge that there might be some level 
of uncertainty around the estimated number of children 
who did not receive MCV1 in 2019. However, as there is 
no underlying probability model upon which the 
WUENIC estimates we used are based, it would be 
difficult to generate levels of uncertainty for the number 
of unvaccinated children. Finally, we did not include 
measles mortality data in this analysis and in the 
scorecard. Although reducing measles mortality is a key 
component of the measles elimination, our scorecard 
highlights readily available metrics that could be used to 
categorise, track, and compare country-level progress.
As it stands, measles will continue to be endemic in 
the west African region after 2020. In this already bleak 
landscape, the ongoing COVID-19 pandemic has 
resulted in disruptions of immunisation systems. 
There is, however, some hope as countries facing 
substantial challenges in reaching measles elimination 
milestones can learn what has worked from their 
neighbours like Cape Verde, The Gambia, and Ghana. 
This shared learning requires a coordinated regional 
effort, whereas countries must adapt such lessons to 
suit their local realities. Countries must prioritise the 
strengthening of their routine immunisation systems 
to ensure they rapidly increase the coverages of MCV1 
and MCV2 that would provide an additional contact for 
other vaccination and child health services in the 
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second year of life. Although this analysis showed that 
SIAs are impactful, they should be targeted at low 
coverage settings, migrants, and hard-to-reach 
subpopulations who are usually missed by the routine 
system.26 It is also imperative that countries strengthen 
their health systems and implement integrated 
strategies to deliver routine services and lifesaving 
interventions to address the health needs of these 
susceptible sub populations. Furthermore, countries 
must strengthen measles case-based surveillance 
systems at subnational levels across the region to 
ensure rapid case detection and laboratory testing of 
suspected cases.39
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